WO2013130584A3 - Formulation contenant ws727713 - Google Patents

Formulation contenant ws727713 Download PDF

Info

Publication number
WO2013130584A3
WO2013130584A3 PCT/US2013/027991 US2013027991W WO2013130584A3 WO 2013130584 A3 WO2013130584 A3 WO 2013130584A3 US 2013027991 W US2013027991 W US 2013027991W WO 2013130584 A3 WO2013130584 A3 WO 2013130584A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid formulation
compound
formulation containing
disintegrant
repellent
Prior art date
Application number
PCT/US2013/027991
Other languages
English (en)
Other versions
WO2013130584A2 (fr
Inventor
Shigeo Takemura
Daisuke Tsunashima
Masakasu MIYAZAKI
Original Assignee
Telsar Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telsar Pharma Inc. filed Critical Telsar Pharma Inc.
Publication of WO2013130584A2 publication Critical patent/WO2013130584A2/fr
Publication of WO2013130584A3 publication Critical patent/WO2013130584A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

La présente invention concerne une formulation solide contenant un composé WS727713 en grande quantité, lequel composé est volumineux, hautement hydrofuge et doté d'une capacité de désintégration à action rapide, et en particulier une formulation solide et notamment une pastille qui a été compactée. La formulation solide contient un produit granulé contenant un composé WS727713 ou son sel et une substance hydrophile, ainsi qu'un délitant.
PCT/US2013/027991 2012-02-29 2013-02-27 Formulation contenant ws727713 WO2013130584A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-044462 2012-02-29
JP2012044462A JP2013180961A (ja) 2012-02-29 2012-02-29 Ｗｓ７２７７１３含有固形製剤

Publications (2)

Publication Number Publication Date
WO2013130584A2 WO2013130584A2 (fr) 2013-09-06
WO2013130584A3 true WO2013130584A3 (fr) 2015-07-02

Family

ID=49083442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/027991 WO2013130584A2 (fr) 2012-02-29 2013-02-27 Formulation contenant ws727713

Country Status (2)

Country Link
JP (1) JP2013180961A (fr)
WO (1) WO2013130584A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613579A (en) * 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
CN110840855B (zh) * 2019-11-27 2022-04-12 哈尔滨珍宝制药有限公司 依托考昔片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070254829A1 (en) * 2004-04-08 2007-11-01 Astellas Pharma Inc. Compound Ws727713
US20090186084A1 (en) * 2006-05-15 2009-07-23 Jean-Charles Schwartz Form of administration of racecadotril
US20100209495A1 (en) * 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US20070254829A1 (en) * 2004-04-08 2007-11-01 Astellas Pharma Inc. Compound Ws727713
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20090186084A1 (en) * 2006-05-15 2009-07-23 Jean-Charles Schwartz Form of administration of racecadotril
US20100209495A1 (en) * 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAGUL, US .: "Current Status Of Tablet Disintegrants: A Review. Pharmainfo.net.", 29 January 2010 (2010-01-29), Retrieved from the Internet <URL:http://web.archive.org/web/20100129033938/http://www.pharmainfo.net/reviews/current-status-tablet-disintegrantsa-review> [retrieved on 20130405] *

Also Published As

Publication number Publication date
WO2013130584A2 (fr) 2013-09-06
JP2013180961A (ja) 2013-09-12

Similar Documents

Publication Publication Date Title
CA2894891A1 (fr) Derives d&#39;acide boronique et leurs utilisations therapeutiques
IL231203A0 (en) Novel selective and reversible ubiquitin-specific inhibitors of protease 7, their pharmaceutical preparations and their therapeutic applications
CA2894892A1 (fr) Derives d&#39;acide boronique et leurs utilisations therapeutiques
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
WO2011138197A3 (fr) Nouveaux comprimés de meloxicam à basse concentration
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
IL232701A (en) Pirazine compounds that inhibit sick kinase, pharmaceutical preparations that contain them and their use in the preparation of drugs
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
WO2014044342A8 (fr) Carbonate d&#39;hydroxyde de magnésium en tant qu&#39;excipient dans des préparations renfermant un principe actif
WO2009120389A8 (fr) Préparations orales et injectables de composés de tétracycline
EP2822561A4 (fr) Composition pharmaceutique liquide stable contenant du piroxicam ou son sel pharmaceutiquement acceptable et de l&#39;acide hyaluronique ou son sel pharmaceutiquement acceptable et procédé de fabrication de cette composition
PT3102187T (pt) Composições farmacêuticas estáveis contendo sitagliptina sob a forma de comprimidos de libertação imediata
WO2010023690A3 (fr) Formulation à libération prolongée d&#39;amisulpride
EP2871187A4 (fr) Nouveau composé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique le contenant à titre de principe actif
WO2013130584A3 (fr) Formulation contenant ws727713
TR201003856A1 (tr) Aktif ajan olarak sefiksim içeren suda çözünebilir formülasyon.
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat
WO2015022560A8 (fr) Composition pharmaceutique stable contenant du bisoprolol et du ramipril
MX2022013541A (es) Composiciones de acido gamma-poliglutamico y zinc.
WO2016020408A3 (fr) Composés pour prévenir l&#39;ototoxicité
WO2011156045A3 (fr) Formulation d&#39;ezatiostat en comprimés
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline
WO2012016646A9 (fr) Comprimés de quétiapine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13754314

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13754314

Country of ref document: EP

Kind code of ref document: A2